Alpha-mannosidosis in a 3.5-year-old girl: A case report

Alpha-mannosidosis in a 3.5-year-old girl: A case report | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Alpha-mannosidosis in a 3.5-year-old girl: A case report Samuel Bonilla Fornes, Maria Pilar Mendez Perez, Maria Eugenia Sanchez Gutierrez, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3952224/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 4 You are reading this latest preprint version Abstract Background: Alpha-mannosidosis is a rare lysosomal storage disease caused by a deficiency of the enzyme alpha-mannosidase. It manifests as a continuous spectrum of signs and symptoms characterized by dysmorphic features, skeletal abnormalities, delayed psychomotor and speech development, impaired hearing, and psychiatric involvement. When suspected, alpha-mannosidosis must be confirmed by biochemical and molecular testing, namely, assessment of blood levels of alpha-mannosidase in leukocytes or fibroblasts and Sanger or new-generation sequencing of the MAN2B1 gene. The disease must be diagnosed and treatment started as quickly as possible, since the long-term prognosis for untreated patients is very poor. Enzyme replacement therapy (ERT, human recombinant alpha-mannosidase) has replaced allogenic stem cell transplant as the mainstay of therapy, thus improving disease-related outcomes with, for example, reduced serum oligosaccharide levels, greater functional capacity, and improved quality of life, all with a good safety profile. Case presentation: We report the seventh case of alpha-mannosidosis in Spain. The patient was a 3.5-year-old girl assessed in the clinical genetics department for developmental retardation and marked dysmorphic features (trigonocephaly, exophthalmos, hypertelorism, and a flat nasal bridge). Radiography revealed shortening and thickening of the long bones, as well as metopic and coronal synostosis. Craniosynostosis was treated with surgery. Assessment of alpha-mannosidase revealed complete absence of enzymatic activity. Genetic analysis revealed the homozygous pathogenic variant of MAN2B1 , c.2248C>T, which is associated with alpha-mannosidosis. Conclusions: ERT is the only currently available pharmacological option for treating children with mild-to-moderate alpha-mannosidosis. Without ERT, patients’ quality of life would be impaired, and their prognosis would worsen significantly. Alpha-mannosidosis Enzyme deficiency Enzyme replacement therapy Quality of life Prognosis Figures Figure 1 Figure 2 1. Background Alpha-mannosidosis is a rare lysosomal storage disease caused by a deficiency in the enzyme alpha mannosidase [ 1 – 5 ] leading to intracellular accumulation of mannose-rich oligosaccharides, with increased excretion in urine [ 2 , 4 , 6 ] and accumulation of mannosylated-glycoproteins in tissue [ 4 ]. The disease manifests as a continuous spectrum of signs and symptoms [ 3 , 4 , 7 , 8 ] characterized by the presence of dysmorphic features, skeletal abnormalities, delayed psychomotor and speech development, hearing impairment, and psychiatric problems [ 1 , 3 , 6 , 9 ]. When alpha-mannosidosis is suspected, the first step is to perform a qualitative urinalysis of mannose-rich oligosaccharides using high-performance liquid chromatography and thin-layer chromatography [ 1 , 3 ]. Serum oligosaccharide levels in affected patients exceed 4.4–4.5 µmol/L, although an abnormal finding is not diagnostic [ 1 – 3 ]. Confirmation is by assessment of blood levels of alpha-mannosidase activity in leukocytes or fibroblasts and by Sanger or new-generation sequencing of the MAN2B1 gene [ 1 , 3 ]. Recent years have seen the development of a new enzyme replacement therapy (ERT) based on human recombinant alpha-mannosidase [ 1 – 4 , 7 , 10 , 11 ]. This approach is now used mainly in mild-to-moderate forms of the disease, leading to reduced mannose-rich oligosaccharide levels, a considerable improvement in motor skills, increased lung capacity, significant increases in immunoglobulin levels, and improved quality of life [ 4 , 5 , 11 , 12 ]. Allogenic stem cell transplantation constitutes an additional option. However, this intervention was associated with morbidity and mortality, as well as with a modest improvement in cognitive ability [ 13 ]. We report the case of a patient whose symptoms were indicative of alpha-mannosidosis. Diagnosis was confirmed based on an appropriate degree of suspicion and biochemical and molecular testing. We report 12 months’ treatment follow-up data. The case we report is the seventh patient diagnosed with alpha-mannosidosis in Spain. 2. Case presentation The patient was a girl aged 3.5 years who was assessed in the clinical genetics department for developmental retardation and mild dysmorphic features. 2.1 Personal and family history The patient’s parents are first cousins. She has a healthy 2-year-old brother. After comprehensive pregnancy monitoring, the patient was born via normal delivery at 40 weeks of gestational age. Somatometric data at birth were normal. Her birth weight was 3280 g. An umbilical hernia had been present since birth. As for psychomotor development, the patient began to roll over at 5 months and walk at 17 months. Language delay was severe, and she remained incontinent at age 3 years. 2.2 Disease history At age 15 months, the patient began to make repetitive movements of her upper and lower limbs owing to nonepileptic paroxysmal disorder. The electroencephalogram was normal. Evaluation in the physiotherapy department at 24 months revealed pes valgus and pes cavus. The patient was assessed by the ENT department owing to hypertrophic tonsils and bilateral serous otitis media. She was admitted to hospital at 2 years and 11 months with pain and inflammation affecting the left knee. Treatment was with arthrocentesis and antibiotic therapy. The physical examination showed her weight to be 14.5 kg (P44), height 94 cm (P25), and head circumference 47.5 cm (P7). Examination of the head revealed trigonocephaly, horizontal palpebral fissures, exophthalmos, hypertelorism, as well as a broad, flat, and depressed nasal bridge. She had full everted lips and macroglossia, a hoarse voice, normal pinnae, and remnants of both upper incisors, which had fractured. Examination revealed a normal thorax, distended abdomen, and umbilical hernia. The spleen was palpable, as was the liver (1 cm). Her limbs were slightly short, and she had normal female genitalia. 2.3 Additional testing The blood work-up revealed normal values for ammonia, pyruvate, lactate, amino acids, and acylcarnitine. Abdominal ultrasound revealed slight splenomegaly (4 mm), umbilical hernia, and rectus abdominis diastasis. Total skeletal radiography (Fig. 1 ) revealed a thick cranial vault with prominent convolutional markings (copper beaten skull) (Figs. 1 A, 1 B), thick ribs (Fig. 1 C), posterior arch fusion defect at L5 (Fig. 1 D), shortening and thickening of the long bones, and slight metaphyseal widening (Figs. 1 E, 1 F). Magnetic resonance of the skull revealed metopic and coronal synostosis and dysgenesis of the corpus callosum (Fig. 2 ). Trigonocephaly and anterior brachycephaly were treated with surgery. The cardiac evaluation was normal. The ophthalmology evaluation revealed no corneal deposits or crystalline lens opacities, and fundoscopy was normal. The patient underwent surgery (adenotonsillectomy and bilateral myringotomy with tubes). Quantitative urinalysis revealed increased excretion of oligosaccharides and normal glycosaminoglycan levels. A study of the enzymatic activity of alpha-mannosidase revealed complete absence of the enzyme. The results of array comparative genomic hybridization were normal. Targeted exome sequencing (by phenotype) for lysosomal storage disease and skeletal dysplasia yielded the homozygous pathogenic variant of MAN2B1 c.2248C > T/pHGVS: p.R750W (missense_variant)/Exon 18/24, with autosomal recessive inheritance (NM_000528.3), which is associated with alpha-mannosidosis. We performed the exome study to assess lysosomal storage disorder and bone dysplasia at the same time as the biochemistry work-up because the mother was pregnant. The condition had to be diagnosed quickly owing to the potential need for a prenatal genetic study during the mother’s current pregnancy. A genetic study of the parents and sibling showed that they were heterozygous for the variant c.2248C > T (p.R750W) in MAN2B1. The mother, who was pregnant, underwent amniocentesis, which revealed homozygous c.2248C > T (p.R750W) of MAN2B1 in the amniotic fluid. The pregnancy was terminated. 2.4. Treatment initiation and outcomes The patient started to receive ERT as an intravenous infusion of velmanase alfa at hospital in June 2022. The starting dose was 1 mg/kg/wk, as indicated in the summary of product characteristics [ 11 ]. This was well tolerated, and no complications were recorded. Twelve months after initiation of treatment, the patient remains stable, with no treatment-related adverse events and good response and tolerability. During this year, the patient’s language improved considerably, and speech-language pathology is also helping, enabling her to develop a wider and more advanced vocabulary and better understanding. Her behavior has also improved, and she now leads a high-quality normal life. The patient’s hearing remains stable. Motor capacity analyzed using the 6-minute walk test (6MWT) and 3-minute stair-climb test (3MSCT) remained stable, with a slight improvement. As for hearing impairment, the patient presented normal audiometry parameters in terms of brainstem auditory evoked potentials at the beginning of treatment and after 12 months. Evaluation in the ENT department revealed mucoserous otitis, adenoid hypertrophy, and pediatric obstructive sleep apnea. In April 2022, the adenoids were removed, and drainage tubes were placed in both ears. 3. Discussion Alpha-mannosidosis (OMIM 248500) is a rare entity belonging to the lysosomal storage disease family. The disorder is caused by a deficiency in the enzyme alpha-mannosidase. Inheritance is autosomal recessive [ 1 – 5 ]. Prevalence is between 1/500,000 and 1/1,000,000 live births [ 1 , 2 , 4 , 5 , 10 ], with only 7 cases reported to date in Spain. The gene responsible for the disease is MAN2B1 , for which more than 155 mutations have been identified [ 1 , 3 , 6 , 10 , 14 ]. MAN2B1 is located at chromosome 19 (19 p13.2- q12) [ 4 , 6 , 14 ]. The correlation between genotype and phenotype is still controversial [ 3 , 6 ]. For years, allogenic stem cell transplant was the only treatment option. However, since 2018, affected patients in Europe have been able to receive ERT based on human recombinant alpha-mannosidase, which reduces serum oligosaccharide levels, thus increasing catabolism and preventing accumulation in tissue [ 4 , 5 , 11 , 13 ]. This approach is indicated for the treatment of non-neurological manifestations—it has not been shown to cross the blood-brain barrier—in patients with mild-to-moderate clinical involvement [ 11 ]. Borgwardt et al. [ 15 ] also recorded an improvement in cognitive and motor function, with reduced oligosaccharide levels in cerebrospinal fluid, blood, and urine [ 2 , 8 , 14 ]. According to the endpoints evaluated in the clinical development of velmanase alfa, the mean relative change in serum oligosaccharides (S-oligo) in the study arm was − 77.6%. In the case we report, urine oligosaccharide levels were measured at the beginning of the treatment, revealing very high values. Motor disturbance was evaluated using the 3MSCT and the 6MWT. An improvement in these parameters, especially in children and after long-term treatment with velmanase alfa, has been reported [ 4 , 5 , 13 , 14 ]. We did not observe motor disturbance at the beginning of treatment because of the patient’s young age, although the condition stabilized and even slightly improved after 12 months of treatment (Table 1 ). Table 1 6-minute walk test (6MWT) and 3-minute stair-climb test (3MSCT) from baseline to the last visit Baseline June 2023 6MWT 343.2 m 396 m 3MSTC 240 steps 254 steps The main symptoms in younger patients are impaired hearing, recurrent otitis, and early language delay (as in the case we report), with wide variability in symptoms, ranging from completely nonverbal patients to patients with clear speech that is inappropriate for their age. Cases of dysarthria have also been reported [ 1 , 3 , 6 ]. Patients rarely exhibit symptoms at birth [ 1 , 3 , 7 ], thus hampering early diagnosis. In the present case, and even though the diagnostic delay was short (3.5 years), it was necessary to monitor symptoms before alpha-mannosidosis was suspected. Impaired language development is characterized by limited vocabulary, poorly intelligible speech, and inappropriate pronunciation [ 6 ], as observed at diagnosis in the present case. After 12 months of ERT, the patient’s language ability had improved considerably, with a much larger vocabulary. Periodic behavioral abnormalities and the presence of psychiatric symptoms (eg, anxiety, depression, hallucinations, and delirium) have been detected in 70% of patients aged 10 to 30 years) [ 6 , 9 ]. Given the young age of the patient, psychiatric symptoms were not present, although we did detect behavioral deficiencies that were reversed after 12 months of treatment. The patient showed signs of global developmental behavioral disorder (eg, an intermittent inappropriate response to her name, poor interaction in play and social contact, and episodes of inappropriate irritability), although these improved after 1 year of treatment. This finding is in line with the results of a recent study on velmanase alfa in children aged < 6 years, in which quality of life was assessed by administering the PEDI questionnaire to the parents. After at least 24 months of treatment with velmanase alfa, raw and scaled scores improved in all children in all domains compared with baseline [ 16 ]. Furthermore, during the clinical development of the drug, quality of life improved, as shown by the EuroQol 5 Dimension-5 Level Questionnaire administered after 48 months of treatment, with absolute change values for the pediatric group of 0.083 (0.136) that exceeded the minimal clinically important difference [ 17 ]. Patients with alpha-mannosidosis have macrocephaly and coarse facial features, such as prominent forehead, broad and rounded eyebrows, flat nasal bridge, macroglossia, and widely spaced teeth, as well as prognathism and short neck [ 1 ]. In line with the red flags pointing to a lysosomal disorder, coarse facial features were present in the case we report (see above). Osteo-skeletal abnormalities in alpha-mannosidosis include multiple dysostoses, genu valgum, kyphosis, scoliosis, asymptomatic osteopenia, sclerotic bone lesions, sternal deformities, hip dysplasia, cranial thickening, and malformed vertebrae [ 1 , 6 ]. In the present case, the main skeletal abnormalities were shortening of long bones and slight metaphyseal widening of the metaphysis. (Fig. 1 E, 1 F). Alterations of the immune system have been reported, mainly in the form of respiratory and gastrointestinal infections, especially during the first decade of life [ 1 , 6 – 8 ]. The central nervous system abnormalities reported include occipital white matter lesions with local or diffuse signal hyperintensity on MRI, cerebellar or cortical atrophy, and thinning of the corpus callosum [ 1 , 9 ]. This finding was observed in the MRI scan performed in the present report, which revealed dysgenesis of the corpus callosum. Delayed myelinization and hydrocephaly have also been reported [ 1 ]. The patient presented with metopic and coronal craniosynostosis. She underwent surgery and progressed well thereafter. Three cases with craniosynostosis have been reported. Craniosynostosis may be a sign of alpha-mannosidosis and can be considered an extension of the clinical spectrum [ 3 , 8 , 18 ]. Our patient had an umbilical hernia. This condition is observed in a variable number of patients [ 18 ]. Despite the diagnostic difficulties, it is very important to diagnose the disease early, given the increasing evidence that the response to treatment is better in children than in adults reinforces the importance of early diagnosis of this disease and treatment with replacement therapy [ 1 , 3 , 4 , 8 , 16 ]. The long-term prognosis for untreated patients is very poor, with progression of cognitive, skeletal, and neuromuscular impairment over decades. Most patients need a wheelchair for basic mobility and assistance with their activities of daily living [ 1 , 8 ]. The decrease in life expectancy is determined by neurological involvement and recurrent infection [ 7 ]. In order to facilitate early diagnosis of alpha-mannosidosis, the pediatrician should take the condition into account in the case of a child with delayed neurodevelopment and dysmorphic features (usually less obvious than in patients with mucopolysaccharidosis). Therefore, it is important to publish reports of cases of alpha-mannosidosis in pediatrics journals. Since recently, ERT with velmanase alfa has been funded by the public health system in Spain, thus improving access to the drug. Therefore, it is very important to highlight that this is the only medication available to treat affected children. Without treatment, patients’ quality of life would be considerably impaired, and prognosis would worsen significantly [ 6 , 11 ]. 4. Conclusions We report a case of alpha-mannosidosis in which diagnosis was confirmed based on an appropriate degree of suspicion and biochemical and molecular testing. This is the seventh such case in Spain. The spectrum of signs and symptoms of alpha-mannosidosis should include craniosynostosis. In order to facilitate the diagnosis of alpha-mannosidosis, the pediatrician should take the condition into account when treating patients with delayed neurodevelopment and dysmorphic features. Diagnosis is sometimes urgent (especially when the mother is pregnant and prenatal testing is necessary). Therefore, molecular testing should be performed together with or before the biochemical study. Treatment with ERT is safe in young children with a good prognosis. Abbreviations ERT enzyme replacement therapy 6MWT 6-minute walk test 3MSCT 3-minute stair-climb test Declarations Ethics approval and consent to participate The patient’s parents gave their consent for the patient to participate in the study and for her medical data and images to be used for publication. Consent for publication The patient’s parents gave their written informed consent for the patient’s medical data and images to be reported in the present article. Availability of data and materials The datasets generated and/or analyzed during the current study are not publicly available because they are from the patient’s medical records but are available from the corresponding authors on reasonable request. Competing interests The authors declare that they have no competing interests. Funding Medical writing for this work was supported by Chiesi Spain S.A.U. including coverage of all publication fees. This funding did not interfere with the study design, data collection, analysis and interpretation of data, the preparation of this article, or the decision to submit it for publication. Authors’ contributions SBF: Data curation; Formal analysis; Resources; Investigation. MPMP:Data curation; Formal analysis; Funding; Investigation; Methodology; Project administration; Resources; Software. MESG: Formal analysis; Investigation; Methodology; Resources. EGG: Conceptualization; Supervision; Validation; Visualization; Writing - review and editing of the original draft. Acknowledgements We are grateful to Thomas O’Boyle for medical writing assistance, which was funded by Chiesi España. References Guffon N, Tylki-Szymanska A, Borgwardt L, Lund AM, Gil-Campos M, Parini R, et al. Recognition of alpha-mannosidosis in paediatric and adult patients: Presentation of a diagnostic algorithm from an international working group. Mol Genet Metab. 2019;126(4):470–4. http://doi.org/10.1016/j.ymgme.2019.01.024 . Zielonka M, Garbade SF, Kölker S, Hoffmann GF, Ries M. Ultra-orphan lysosomal storage diseases: A cross-sectional quantitative analysis of the natural history of alpha-mannosidosis. J Inherit Metab Dis. 2019;42(5):975–83. http://doi.org/10.1002/jimd.12138 . Lehalle D, Colombo R, O’Grady M, Héron B, Houcinat N, Kuentz P, et al. Hearing impairment as an early sign of alpha-mannosidosis in children with a mild phenotype: Report of seven new cases. Am J Med Genet A. 2019;179(9):1756–63. http://doi.org/10.1002/ajmg.a.61273 . Harmatz P, Cattaeo F, Ardigò D, Geraci S, Hennermann JB, Guffon N, et al. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis. Mol Genet Metab. 2008;124(2):152–60. http://doi.org/10.1016/j.ymgme.2018.04.003 . Lund AM, Borgwardt L, Cattaneo F, Ardigò D, Geraci S, Gil-Campos M, et al. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. J Inherit Metab Dis. 2018;41(6):1225–33. http://doi.org/10.1007/s10545-018-0175-2 . Malm D, Stensland HMFR, Edvardsen Ø, Nilssen Ø. The natural course and complications of alpha-mannosidosis–a retrospective and descriptive study. J Inherit Metab Dis. 2014;37(1):79–82. http://doi.org/10.1007/s10545-013-9622-2 . Nir V, Bentur L, Tal G, Gur M, Gut G, Ilivitzki A, et al. Comprehensive cardiopulmonary assessment in α mannosidosis. Pediatr Pulmonol. 2020;55(9):2348–53. http://doi.org/10.1002/ppul.24864 . Verrecchia E, Sicignano LL, Massaro M, Rocco R, Silvestri G, Rossi S, et al. Caregivers' and Physicians' Perspectives on Alpha-Mannosidosis: A Report from Italy. Adv Ther. 2021;38(1):1–10. http://doi.org/10.1007/s12325-020-01574-w . Majovska J, Nestrasil I, Paulson A, Nascene D, Jurickova K, Hlvata A, et al. White matter alteration and cerebellar atrophy are hallmarks of brain MRI in alpha-mannosidosis. Mol Genet Metab. 2021;132(3):189–97. http://doi.org/10.1016/j.ymgme.2020.11.008 . Wiesinger T, Schwarz M, Mechtler TP, Liebmann-Reindl S, Streubel B, Kasper DC. α-Mannosidosis - An underdiagnosed lysosomal storage disease in individuals with an 'MPS-like' phenotype. Mol Genet Metab. 2020;130(2):149–52. http://doi.org/10.1016/j.ymgme.2020.04.001 . European Medicines Agency (EMA). European Public Assessment Report Lamzede®. 2018. https://www.ema.europa.eu/en/documents/assessment-report/lamzede-epar-public-assessment-report_en.pdf . Borgwardt L, Guffon N, Amraoui Y, Dali CI, De Meirleir L, Gil-Campos M, et al. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. J Inherit Metab Dis. 2018;41(6):1215–23. http://doi.org/10.1007/s10545-018-0185-0 . Mynarek M, Tolar J, Albert MH, Escolar ML, Boelens JJ, Cowan MJ, et al. Allogeneic hematopoietic SCT for alpha-mannidosis: an analysis of 17 patients. Bone Marrow Transpl. 2021;47(3):352–9. doi.org/10.1038/bmt.2011.99 . Hennermann JB, Guffon N, Cattaneo F, Ceravolo F, Borgwardt L, Lund AM, et al. The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis. Orphanet J Rare Dis. 2020;15(1):271. http://doi.org/10.1186/s13023-020-01549-8 . Borgwardt L, Dali CI, Fogh J, Månsson JE, Olsen KJ, Beck HC, et al. Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study. J Inherit Metab Dis. 2013;36(6):1015–24. http://doi.org/10.1007/s10545-013-9595-1 . Guffon N, Konstantopoulou V, Hennermann JB, Muschol N, Bruno I, Tummolo A, et al. Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: A phase 2, open label, multicenter study. J Inherit Metab Dis. 2023;6(4):705–19. http://doi.org/10.1002/jimd.12602 . Borgwardt L, Guffon N, Amraoui Y, Jones SA, De Meirleir L, Lund AM, et al. Health Related Quality of Life, Disability, and Pain in Alpha Mannosidosis: Long-Term Data of Enzyme Replacement Therapy With Velmanase Alfa (Human Recombinant Alpha Mannosidase). J Inborn Errors Metab Screen. 2018;6. http://doi.org/10.1177/2326409818796854 . Lipiński P, Rózdzynska-Swiątkowska A, Iwanicka-Pronicka K, Perkowska B, Pokora P, Tylki-Szymańska A. Long-term outcome of patients with alpha-mannosidosis – A single center study. Mol Genet Metab Rep. 2021;30:100826. http://doi.org/10.1016/j.ymgmr.2021.100826 . Supplementary Files CAREchecklistEnglish2013IJP.docx Cite Share Download PDF Status: Under Review Version 1 posted Reviewers agreed at journal 04 Mar, 2024 Reviewers invited by journal 03 Mar, 2024 Editor assigned by journal 15 Feb, 2024 First submitted to journal 14 Feb, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3952224","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":276097316,"identity":"d96cbaa9-e10e-412d-a911-974c3f2060f7","order_by":0,"name":"Samuel Bonilla Fornes","email":"","orcid":"","institution":"Hospital Materno Infantil, SES, Badajoz, Spain","correspondingAuthor":false,"prefix":"","firstName":"Samuel","middleName":"Bonilla","lastName":"Fornes","suffix":""},{"id":276097317,"identity":"d3d046d6-1c97-409f-a014-3ea6f7808493","order_by":1,"name":"Maria Pilar Mendez Perez","email":"","orcid":"","institution":"Hospital Materno Infantil, SES, Badajoz, Spain","correspondingAuthor":false,"prefix":"","firstName":"Maria","middleName":"Pilar Mendez","lastName":"Perez","suffix":""},{"id":276097318,"identity":"826e888c-8062-47d4-a039-22e90cd14e0c","order_by":2,"name":"Maria Eugenia Sanchez Gutierrez","email":"","orcid":"","institution":"Hospital Materno Infantil, SES, Badajoz, Spain","correspondingAuthor":false,"prefix":"","firstName":"Maria","middleName":"Eugenia Sanchez","lastName":"Gutierrez","suffix":""},{"id":276097319,"identity":"c654efad-3cbe-4af2-a78d-a8496b921d4e","order_by":3,"name":"Enrique Galán Gómez","email":"data:image/png;base64,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","orcid":"https://orcid.org/0000-0002-9516-8230","institution":"Hospital Materno Infantil SES, Badajoz, Spain","correspondingAuthor":true,"prefix":"","firstName":"Enrique","middleName":"Galán","lastName":"Gómez","suffix":""}],"badges":[],"createdAt":"2024-02-12 23:54:09","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3952224/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3952224/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":52106238,"identity":"0ef9d4d3-b822-431d-bfaa-85a74916bc6f","added_by":"auto","created_at":"2024-03-06 19:37:03","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":121109,"visible":true,"origin":"","legend":"\u003cp\u003eBone examination in a patient aged 3.5 years. A and B, Coronal and sagittal images showing copper beaten skull and cranial vault thickening. C, Thick ribs, sagittal view. D, Fusion defect on posterior arch of L5. E and F, Slightly thickened short bones in limbs and widening in metaphyses.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-3952224/v1/a0cd512d95c8b485ff8902ac.png"},{"id":52106240,"identity":"ab7ec345-a00e-4870-b92b-545734efbd9b","added_by":"auto","created_at":"2024-03-06 19:37:03","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":206895,"visible":true,"origin":"","legend":"\u003cp\u003eSagittal view on cranial magnetic resonance imaging. Note dysgenesis of the corpus callosum.\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-3952224/v1/a2b5a4c39845c407786b0a5e.png"},{"id":52106764,"identity":"d57cc08b-0a39-40a4-bb99-ac488717aebd","added_by":"auto","created_at":"2024-03-06 19:45:03","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":711685,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3952224/v1/24ffcd2a-d5a0-492b-aa78-29f24d84ef20.pdf"},{"id":52106241,"identity":"1ce5c86a-7d8e-40b2-a835-7c30eb06f03d","added_by":"auto","created_at":"2024-03-06 19:37:03","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":81384,"visible":true,"origin":"","legend":"","description":"","filename":"CAREchecklistEnglish2013IJP.docx","url":"https://assets-eu.researchsquare.com/files/rs-3952224/v1/427e3b5c77e5c48c8290e517.docx"}],"financialInterests":"","formattedTitle":"Alpha-mannosidosis in a 3.5-year-old girl: A case report","fulltext":[{"header":"1. Background","content":"\u003cp\u003eAlpha-mannosidosis is a rare lysosomal storage disease caused by a deficiency in the enzyme alpha mannosidase [\u003cspan additionalcitationids=\"CR2 CR3 CR4\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e] leading to intracellular accumulation of mannose-rich oligosaccharides, with increased excretion in urine [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e] and accumulation of mannosylated-glycoproteins in tissue [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe disease manifests as a continuous spectrum of signs and symptoms [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] characterized by the presence of dysmorphic features, skeletal abnormalities, delayed psychomotor and speech development, hearing impairment, and psychiatric problems [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eWhen alpha-mannosidosis is suspected, the first step is to perform a qualitative urinalysis of mannose-rich oligosaccharides using high-performance liquid chromatography and thin-layer chromatography [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Serum oligosaccharide levels in affected patients exceed 4.4\u0026ndash;4.5 \u0026micro;mol/L, although an abnormal finding is not diagnostic [\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Confirmation is by assessment of blood levels of alpha-mannosidase activity in leukocytes or fibroblasts and by Sanger or new-generation sequencing of the \u003cem\u003eMAN2B1\u003c/em\u003e gene [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eRecent years have seen the development of a new enzyme replacement therapy (ERT) based on human recombinant alpha-mannosidase [\u003cspan additionalcitationids=\"CR2 CR3\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. This approach is now used mainly in mild-to-moderate forms of the disease, leading to reduced mannose-rich oligosaccharide levels, a considerable improvement in motor skills, increased lung capacity, significant increases in immunoglobulin levels, and improved quality of life [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAllogenic stem cell transplantation constitutes an additional option. However, this intervention was associated with morbidity and mortality, as well as with a modest improvement in cognitive ability [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eWe report the case of a patient whose symptoms were indicative of alpha-mannosidosis. Diagnosis was confirmed based on an appropriate degree of suspicion and biochemical and molecular testing. We report 12 months\u0026rsquo; treatment follow-up data. The case we report is the seventh patient diagnosed with alpha-mannosidosis in Spain.\u003c/p\u003e"},{"header":"2. Case presentation","content":"\u003cp\u003eThe patient was a girl aged 3.5 years who was assessed in the clinical genetics department for developmental retardation and mild dysmorphic features.\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1 Personal and family history\u003c/h2\u003e \u003cp\u003e The patient\u0026rsquo;s parents are first cousins. She has a healthy 2-year-old brother.\u003c/p\u003e \u003cp\u003eAfter comprehensive pregnancy monitoring, the patient was born via normal delivery at 40 weeks of gestational age. Somatometric data at birth were normal. Her birth weight was 3280 g. An umbilical hernia had been present since birth. As for psychomotor development, the patient began to roll over at 5 months and walk at 17 months. Language delay was severe, and she remained incontinent at age 3 years.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2 Disease history\u003c/h2\u003e \u003cp\u003eAt age 15 months, the patient began to make repetitive movements of her upper and lower limbs owing to nonepileptic paroxysmal disorder. The electroencephalogram was normal. Evaluation in the physiotherapy department at 24 months revealed pes valgus and pes cavus. The patient was assessed by the ENT department owing to hypertrophic tonsils and bilateral serous otitis media. She was admitted to hospital at 2 years and 11 months with pain and inflammation affecting the left knee. Treatment was with arthrocentesis and antibiotic therapy.\u003c/p\u003e \u003cp\u003eThe physical examination showed her weight to be 14.5 kg (P44), height 94 cm (P25), and head circumference 47.5 cm (P7). Examination of the head revealed trigonocephaly, horizontal palpebral fissures, exophthalmos, hypertelorism, as well as a broad, flat, and depressed nasal bridge. She had full everted lips and macroglossia, a hoarse voice, normal pinnae, and remnants of both upper incisors, which had fractured. Examination revealed a normal thorax, distended abdomen, and umbilical hernia. The spleen was palpable, as was the liver (1 cm). Her limbs were slightly short, and she had normal female genitalia.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3 Additional testing\u003c/h2\u003e \u003cp\u003eThe blood work-up revealed normal values for ammonia, pyruvate, lactate, amino acids, and acylcarnitine.\u003c/p\u003e \u003cp\u003eAbdominal ultrasound revealed slight splenomegaly (4 mm), umbilical hernia, and rectus abdominis diastasis.\u003c/p\u003e \u003cp\u003eTotal skeletal radiography (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) revealed a thick cranial vault with prominent convolutional markings (copper beaten skull) (Figs.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB), thick ribs (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC), posterior arch fusion defect at L5 (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD), shortening and thickening of the long bones, and slight metaphyseal widening (Figs.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eMagnetic resonance of the skull revealed metopic and coronal synostosis and dysgenesis of the corpus callosum (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eTrigonocephaly and anterior brachycephaly were treated with surgery. The cardiac evaluation was normal. The ophthalmology evaluation revealed no corneal deposits or crystalline lens opacities, and fundoscopy was normal.\u003c/p\u003e \u003cp\u003eThe patient underwent surgery (adenotonsillectomy and bilateral myringotomy with tubes).\u003c/p\u003e \u003cp\u003eQuantitative urinalysis revealed increased excretion of oligosaccharides and normal glycosaminoglycan levels. A study of the enzymatic activity of alpha-mannosidase revealed complete absence of the enzyme.\u003c/p\u003e \u003cp\u003eThe results of array comparative genomic hybridization were normal.\u003c/p\u003e \u003cp\u003eTargeted exome sequencing (by phenotype) for lysosomal storage disease and skeletal dysplasia yielded the homozygous pathogenic variant of \u003cem\u003eMAN2B1\u003c/em\u003e c.2248C\u0026thinsp;\u0026gt;\u0026thinsp;T/pHGVS: p.R750W (missense_variant)/Exon 18/24, with autosomal recessive inheritance (NM_000528.3), which is associated with alpha-mannosidosis. We performed the exome study to assess lysosomal storage disorder and bone dysplasia at the same time as the biochemistry work-up because the mother was pregnant. The condition had to be diagnosed quickly owing to the potential need for a prenatal genetic study during the mother\u0026rsquo;s current pregnancy.\u003c/p\u003e \u003cp\u003eA genetic study of the parents and sibling showed that they were heterozygous for the variant c.2248C\u0026thinsp;\u0026gt;\u0026thinsp;T (p.R750W) in \u003cem\u003eMAN2B1.\u003c/em\u003e The mother, who was pregnant, underwent amniocentesis, which revealed homozygous c.2248C\u0026thinsp;\u0026gt;\u0026thinsp;T (p.R750W) of \u003cem\u003eMAN2B1\u003c/em\u003e in the amniotic fluid. The pregnancy was terminated.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.4. Treatment initiation and outcomes\u003c/h2\u003e \u003cp\u003eThe patient started to receive ERT as an intravenous infusion of velmanase alfa at hospital in June 2022. The starting dose was 1 mg/kg/wk, as indicated in the summary of product characteristics [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. This was well tolerated, and no complications were recorded.\u003c/p\u003e \u003cp\u003eTwelve months after initiation of treatment, the patient remains stable, with no treatment-related adverse events and good response and tolerability. During this year, the patient\u0026rsquo;s language improved considerably, and speech-language pathology is also helping, enabling her to develop a wider and more advanced vocabulary and better understanding. Her behavior has also improved, and she now leads a high-quality normal life. The patient\u0026rsquo;s hearing remains stable.\u003c/p\u003e \u003cp\u003eMotor capacity analyzed using the 6-minute walk test (6MWT) and 3-minute stair-climb test (3MSCT) remained stable, with a slight improvement.\u003c/p\u003e \u003cp\u003eAs for hearing impairment, the patient presented normal audiometry parameters in terms of brainstem auditory evoked potentials at the beginning of treatment and after 12 months. Evaluation in the ENT department revealed mucoserous otitis, adenoid hypertrophy, and pediatric obstructive sleep apnea. In April 2022, the adenoids were removed, and drainage tubes were placed in both ears.\u003c/p\u003e \u003c/div\u003e"},{"header":"3. Discussion","content":"\u003cp\u003eAlpha-mannosidosis (OMIM 248500) is a rare entity belonging to the lysosomal storage disease family.\u003c/p\u003e \u003cp\u003eThe disorder is caused by a deficiency in the enzyme alpha-mannosidase. Inheritance is autosomal recessive [\u003cspan additionalcitationids=\"CR2 CR3 CR4\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Prevalence is between 1/500,000 and 1/1,000,000 live births [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e], with only 7 cases reported to date in Spain.\u003c/p\u003e \u003cp\u003eThe gene responsible for the disease is \u003cem\u003eMAN2B1\u003c/em\u003e, for which more than 155 mutations have been identified [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. \u003cem\u003eMAN2B1\u003c/em\u003e is located at chromosome 19 (19 p13.2- q12) [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. The correlation between genotype and phenotype is still controversial [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFor years, allogenic stem cell transplant was the only treatment option. However, since 2018, affected patients in Europe have been able to receive ERT based on human recombinant alpha-mannosidase, which reduces serum oligosaccharide levels, thus increasing catabolism and preventing accumulation in tissue [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. This approach is indicated for the treatment of non-neurological manifestations\u0026mdash;it has not been shown to cross the blood-brain barrier\u0026mdash;in patients with mild-to-moderate clinical involvement [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. Borgwardt et al. [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e] also recorded an improvement in cognitive and motor function, with reduced oligosaccharide levels in cerebrospinal fluid, blood, and urine [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAccording to the endpoints evaluated in the clinical development of velmanase alfa, the mean relative change in serum oligosaccharides (S-oligo) in the study arm was \u0026minus;\u0026thinsp;77.6%. In the case we report, urine oligosaccharide levels were measured at the beginning of the treatment, revealing very high values.\u003c/p\u003e \u003cp\u003eMotor disturbance was evaluated using the 3MSCT and the 6MWT. An improvement in these parameters, especially in children and after long-term treatment with velmanase alfa, has been reported [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. We did not observe motor disturbance at the beginning of treatment because of the patient\u0026rsquo;s young age, although the condition stabilized and even slightly improved after 12 months of treatment (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003e6-minute walk test (6MWT) and 3-minute stair-climb test (3MSCT) from baseline to the last visit\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBaseline\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJune 2023\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6MWT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e343.2 m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e396 m\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3MSTC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e240 steps\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e254 steps\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eThe main symptoms in younger patients are impaired hearing, recurrent otitis, and early language delay (as in the case we report), with wide variability in symptoms, ranging from completely nonverbal patients to patients with clear speech that is inappropriate for their age. Cases of dysarthria have also been reported [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Patients rarely exhibit symptoms at birth [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e], thus hampering early diagnosis. In the present case, and even though the diagnostic delay was short (3.5 years), it was necessary to monitor symptoms before alpha-mannosidosis was suspected.\u003c/p\u003e \u003cp\u003eImpaired language development is characterized by limited vocabulary, poorly intelligible speech, and inappropriate pronunciation [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e], as observed at diagnosis in the present case. After 12 months of ERT, the patient\u0026rsquo;s language ability had improved considerably, with a much larger vocabulary.\u003c/p\u003e \u003cp\u003ePeriodic behavioral abnormalities and the presence of psychiatric symptoms (eg, anxiety, depression, hallucinations, and delirium) have been detected in 70% of patients aged 10 to 30 years) [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Given the young age of the patient, psychiatric symptoms were not present, although we did detect behavioral deficiencies that were reversed after 12 months of treatment. The patient showed signs of global developmental behavioral disorder (eg, an intermittent inappropriate response to her name, poor interaction in play and social contact, and episodes of inappropriate irritability), although these improved after 1 year of treatment. This finding is in line with the results of a recent study on velmanase alfa in children aged\u0026thinsp;\u0026lt;\u0026thinsp;6 years, in which quality of life was assessed by administering the PEDI questionnaire to the parents. After at least 24 months of treatment with velmanase alfa, raw and scaled scores improved in all children in all domains compared with baseline [\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Furthermore, during the clinical development of the drug, quality of life improved, as shown by the EuroQol 5 Dimension-5 Level Questionnaire administered after 48 months of treatment, with absolute change values for the pediatric group of 0.083 (0.136) that exceeded the minimal clinically important difference [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e].\u003c/p\u003e \u003cp\u003ePatients with alpha-mannosidosis have macrocephaly and coarse facial features, such as prominent forehead, broad and rounded eyebrows, flat nasal bridge, macroglossia, and widely spaced teeth, as well as prognathism and short neck [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. In line with the red flags pointing to a lysosomal disorder, coarse facial features were present in the case we report (see above).\u003c/p\u003e \u003cp\u003eOsteo-skeletal abnormalities in alpha-mannosidosis include multiple dysostoses, genu valgum, kyphosis, scoliosis, asymptomatic osteopenia, sclerotic bone lesions, sternal deformities, hip dysplasia, cranial thickening, and malformed vertebrae [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. In the present case, the main skeletal abnormalities were shortening of long bones and slight metaphyseal widening of the metaphysis. (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE, \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF).\u003c/p\u003e \u003cp\u003eAlterations of the immune system have been reported, mainly in the form of respiratory and gastrointestinal infections, especially during the first decade of life [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan additionalcitationids=\"CR7\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe central nervous system abnormalities reported include occipital white matter lesions with local or diffuse signal hyperintensity on MRI, cerebellar or cortical atrophy, and thinning of the corpus callosum [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. This finding was observed in the MRI scan performed in the present report, which revealed dysgenesis of the corpus callosum. Delayed myelinization and hydrocephaly have also been reported [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe patient presented with metopic and coronal craniosynostosis. She underwent surgery and progressed well thereafter. Three cases with craniosynostosis have been reported. Craniosynostosis may be a sign of alpha-mannosidosis and can be considered an extension of the clinical spectrum [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eOur patient had an umbilical hernia. This condition is observed in a variable number of patients [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eDespite the diagnostic difficulties, it is very important to diagnose the disease early, given the increasing evidence that the response to treatment is better in children than in adults reinforces the importance of early diagnosis of this disease and treatment with replacement therapy [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. The long-term prognosis for untreated patients is very poor, with progression of cognitive, skeletal, and neuromuscular impairment over decades. Most patients need a wheelchair for basic mobility and assistance with their activities of daily living [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. The decrease in life expectancy is determined by neurological involvement and recurrent infection [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn order to facilitate early diagnosis of alpha-mannosidosis, the pediatrician should take the condition into account in the case of a child with delayed neurodevelopment and dysmorphic features (usually less obvious than in patients with mucopolysaccharidosis). Therefore, it is important to publish reports of cases of alpha-mannosidosis in pediatrics journals.\u003c/p\u003e \u003cp\u003eSince recently, ERT with velmanase alfa has been funded by the public health system in Spain, thus improving access to the drug. Therefore, it is very important to highlight that this is the only medication available to treat affected children. Without treatment, patients\u0026rsquo; quality of life would be considerably impaired, and prognosis would worsen significantly [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e"},{"header":"4. Conclusions","content":"\u003cp\u003eWe report a case of alpha-mannosidosis in which diagnosis was confirmed based on an appropriate degree of suspicion and biochemical and molecular testing. This is the seventh such case in Spain.\u003c/p\u003e \u003cp\u003eThe spectrum of signs and symptoms of alpha-mannosidosis should include craniosynostosis.\u003c/p\u003e \u003cp\u003eIn order to facilitate the diagnosis of alpha-mannosidosis, the pediatrician should take the condition into account when treating patients with delayed neurodevelopment and dysmorphic features.\u003c/p\u003e \u003cp\u003eDiagnosis is sometimes urgent (especially when the mother is pregnant and prenatal testing is necessary). Therefore, molecular testing should be performed together with or before the biochemical study.\u003c/p\u003e \u003cp\u003eTreatment with ERT is safe in young children with a good prognosis.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eERT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eenzyme replacement therapy\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003e6MWT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003e6-minute walk test\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003e3MSCT\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003e3-minute stair-climb test\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe patient’s parents gave their consent for the patient to participate in the study and for her medical data and images to be used for publication.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe patient’s parents gave their written informed consent for the patient’s medical data and images to be reported in the present article.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated and/or analyzed during the current study are not publicly available because they are from the patient’s medical records but are available from the corresponding authors on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMedical writing for this work was supported by Chiesi Spain S.A.U. including coverage of all publication fees. This funding did not interfere with the study design, data collection, analysis and interpretation of data, the preparation of this article, or the decision to submit it for publication.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors’ contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSBF: Data curation; Formal analysis; Resources; Investigation.\u003c/p\u003e\n\u003cp\u003eMPMP:Data curation; Formal analysis; Funding; Investigation; Methodology; Project administration; Resources; Software.\u003c/p\u003e\n\u003cp\u003eMESG: Formal analysis; Investigation; Methodology; Resources.\u003c/p\u003e\n\u003cp\u003eEGG: Conceptualization; Supervision; Validation; Visualization; Writing - review and editing of the original draft.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe are grateful to Thomas O’Boyle for medical writing assistance, which was funded by Chiesi España.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eGuffon N, Tylki-Szymanska A, Borgwardt L, Lund AM, Gil-Campos M, Parini R, et al. Recognition of alpha-mannosidosis in paediatric and adult patients: Presentation of a diagnostic algorithm from an international working group. Mol Genet Metab. 2019;126(4):470\u0026ndash;4. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1016/j.ymgme.2019.01.024\u003c/span\u003e\u003cspan address=\"10.1016/j.ymgme.2019.01.024\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZielonka M, Garbade SF, K\u0026ouml;lker S, Hoffmann GF, Ries M. Ultra-orphan lysosomal storage diseases: A cross-sectional quantitative analysis of the natural history of alpha-mannosidosis. J Inherit Metab Dis. 2019;42(5):975\u0026ndash;83. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1002/jimd.12138\u003c/span\u003e\u003cspan address=\"10.1002/jimd.12138\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLehalle D, Colombo R, O\u0026rsquo;Grady M, H\u0026eacute;ron B, Houcinat N, Kuentz P, et al. Hearing impairment as an early sign of alpha-mannosidosis in children with a mild phenotype: Report of seven new cases. Am J Med Genet A. 2019;179(9):1756\u0026ndash;63. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1002/ajmg.a.61273\u003c/span\u003e\u003cspan address=\"10.1002/ajmg.a.61273\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHarmatz P, Cattaeo F, Ardig\u0026ograve; D, Geraci S, Hennermann JB, Guffon N, et al. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis. Mol Genet Metab. 2008;124(2):152\u0026ndash;60. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1016/j.ymgme.2018.04.003\u003c/span\u003e\u003cspan address=\"10.1016/j.ymgme.2018.04.003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLund AM, Borgwardt L, Cattaneo F, Ardig\u0026ograve; D, Geraci S, Gil-Campos M, et al. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. J Inherit Metab Dis. 2018;41(6):1225\u0026ndash;33. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1007/s10545-018-0175-2\u003c/span\u003e\u003cspan address=\"10.1007/s10545-018-0175-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMalm D, Stensland HMFR, Edvardsen \u0026Oslash;, Nilssen \u0026Oslash;. The natural course and complications of alpha-mannosidosis\u0026ndash;a retrospective and descriptive study. J Inherit Metab Dis. 2014;37(1):79\u0026ndash;82. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1007/s10545-013-9622-2\u003c/span\u003e\u003cspan address=\"10.1007/s10545-013-9622-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNir V, Bentur L, Tal G, Gur M, Gut G, Ilivitzki A, et al. Comprehensive cardiopulmonary assessment in α mannosidosis. Pediatr Pulmonol. 2020;55(9):2348\u0026ndash;53. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1002/ppul.24864\u003c/span\u003e\u003cspan address=\"10.1002/ppul.24864\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVerrecchia E, Sicignano LL, Massaro M, Rocco R, Silvestri G, Rossi S, et al. Caregivers' and Physicians' Perspectives on Alpha-Mannosidosis: A Report from Italy. Adv Ther. 2021;38(1):1\u0026ndash;10. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1007/s12325-020-01574-w\u003c/span\u003e\u003cspan address=\"10.1007/s12325-020-01574-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMajovska J, Nestrasil I, Paulson A, Nascene D, Jurickova K, Hlvata A, et al. White matter alteration and cerebellar atrophy are hallmarks of brain MRI in alpha-mannosidosis. Mol Genet Metab. 2021;132(3):189\u0026ndash;97. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1016/j.ymgme.2020.11.008\u003c/span\u003e\u003cspan address=\"10.1016/j.ymgme.2020.11.008\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWiesinger T, Schwarz M, Mechtler TP, Liebmann-Reindl S, Streubel B, Kasper DC. α-Mannosidosis - An underdiagnosed lysosomal storage disease in individuals with an 'MPS-like' phenotype. Mol Genet Metab. 2020;130(2):149\u0026ndash;52. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1016/j.ymgme.2020.04.001\u003c/span\u003e\u003cspan address=\"10.1016/j.ymgme.2020.04.001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEuropean Medicines Agency (EMA). European Public Assessment Report Lamzede\u0026reg;. 2018. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ema.europa.eu/en/documents/assessment-report/lamzede-epar-public-assessment-report_en.pdf\u003c/span\u003e\u003cspan address=\"https://www.ema.europa.eu/en/documents/assessment-report/lamzede-epar-public-assessment-report_en.pdf\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBorgwardt L, Guffon N, Amraoui Y, Dali CI, De Meirleir L, Gil-Campos M, et al. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. J Inherit Metab Dis. 2018;41(6):1215\u0026ndash;23. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1007/s10545-018-0185-0\u003c/span\u003e\u003cspan address=\"10.1007/s10545-018-0185-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMynarek M, Tolar J, Albert MH, Escolar ML, Boelens JJ, Cowan MJ, et al. Allogeneic hematopoietic SCT for alpha-mannidosis: an analysis of 17 patients. Bone Marrow Transpl. 2021;47(3):352\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003edoi.org/10.1038/bmt.2011.99\u003c/span\u003e\u003cspan address=\"10.1038/bmt.2011.99\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHennermann JB, Guffon N, Cattaneo F, Ceravolo F, Borgwardt L, Lund AM, et al. The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis. Orphanet J Rare Dis. 2020;15(1):271. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1186/s13023-020-01549-8\u003c/span\u003e\u003cspan address=\"10.1186/s13023-020-01549-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBorgwardt L, Dali CI, Fogh J, M\u0026aring;nsson JE, Olsen KJ, Beck HC, et al. Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study. J Inherit Metab Dis. 2013;36(6):1015\u0026ndash;24. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1007/s10545-013-9595-1\u003c/span\u003e\u003cspan address=\"10.1007/s10545-013-9595-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuffon N, Konstantopoulou V, Hennermann JB, Muschol N, Bruno I, Tummolo A, et al. Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: A phase 2, open label, multicenter study. J Inherit Metab Dis. 2023;6(4):705\u0026ndash;19. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1002/jimd.12602\u003c/span\u003e\u003cspan address=\"10.1002/jimd.12602\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBorgwardt L, Guffon N, Amraoui Y, Jones SA, De Meirleir L, Lund AM, et al. Health Related Quality of Life, Disability, and Pain in Alpha Mannosidosis: Long-Term Data of Enzyme Replacement Therapy With Velmanase Alfa (Human Recombinant Alpha Mannosidase). J Inborn Errors Metab Screen. 2018;6. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1177/2326409818796854\u003c/span\u003e\u003cspan address=\"10.1177/2326409818796854\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLipiński P, R\u0026oacute;zdzynska-Swiątkowska A, Iwanicka-Pronicka K, Perkowska B, Pokora P, Tylki-Szymańska A. Long-term outcome of patients with alpha-mannosidosis \u0026ndash; A single center study. Mol Genet Metab Rep. 2021;30:100826. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://doi.org/10.1016/j.ymgmr.2021.100826\u003c/span\u003e\u003cspan address=\"10.1016/j.ymgmr.2021.100826\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"italian-journal-of-pediatrics","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"itjp","sideBox":"Learn more about [Italian Journal of Pediatrics](http://ijponline.biomedcentral.com)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/ITJP/default.aspx","title":"Italian Journal of Pediatrics","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Alpha-mannosidosis, Enzyme deficiency, Enzyme replacement therapy, Quality of life, Prognosis","lastPublishedDoi":"10.21203/rs.3.rs-3952224/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3952224/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground:\u003c/strong\u003e Alpha-mannosidosis is a rare lysosomal storage disease caused by a deficiency of the enzyme alpha-mannosidase. It manifests as a continuous spectrum of signs and symptoms characterized by dysmorphic features, skeletal abnormalities, delayed psychomotor and speech development, impaired hearing, and psychiatric involvement.\u003c/p\u003e\n\u003cp\u003eWhen suspected, alpha-mannosidosis must be confirmed by biochemical and molecular testing, namely, assessment of blood levels of alpha-mannosidase in leukocytes or fibroblasts and Sanger or new-generation sequencing of the \u003cem\u003eMAN2B1 \u003c/em\u003egene. The disease must be diagnosed and treatment started as quickly as possible, since the long-term prognosis for untreated patients is very poor. Enzyme replacement therapy (ERT, human recombinant alpha-mannosidase) has replaced allogenic stem cell transplant as the mainstay of therapy, thus improving disease-related outcomes with, for example, reduced serum oligosaccharide levels, greater functional capacity, and improved quality of life, all with a good safety profile.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCase presentation:\u003c/strong\u003e We report the seventh case of alpha-mannosidosis in Spain. The patient was a 3.5-year-old girl assessed in the clinical genetics department for developmental retardation and marked dysmorphic features (trigonocephaly, exophthalmos, hypertelorism, and a flat nasal bridge). Radiography revealed shortening and thickening of the long bones, as well as metopic and coronal synostosis. Craniosynostosis was treated with surgery. Assessment of alpha-mannosidase revealed complete absence of enzymatic activity. Genetic analysis revealed the homozygous pathogenic variant of \u003cem\u003eMAN2B1\u003c/em\u003e, c.2248C\u0026gt;T, which is associated with alpha-mannosidosis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions:\u003c/strong\u003e ERT is the only currently available pharmacological option for treating children with mild-to-moderate alpha-mannosidosis. Without ERT, patients’ quality of life would be impaired, and their prognosis would worsen significantly.\u003c/p\u003e","manuscriptTitle":"Alpha-mannosidosis in a 3.5-year-old girl: A case report","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-03-06 19:36:58","doi":"10.21203/rs.3.rs-3952224/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"reviewerAgreed","content":"","date":"2024-03-04T13:35:34+00:00","index":0,"fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-03-03T22:52:10+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-02-16T03:40:25+00:00","index":"","fulltext":""},{"type":"submitted","content":"Italian Journal of Pediatrics","date":"2024-02-15T03:18:05+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"italian-journal-of-pediatrics","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"itjp","sideBox":"Learn more about [Italian Journal of Pediatrics](http://ijponline.biomedcentral.com)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/ITJP/default.aspx","title":"Italian Journal of Pediatrics","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"d34409ad-80b8-4755-b2dc-10d06918200b","owner":[],"postedDate":"March 6th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2024-03-06T19:36:59+00:00","versionOfRecord":[],"versionCreatedAt":"2024-03-06 19:36:58","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3952224","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3952224","identity":"rs-3952224","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}